Post-surgery bioluminescence imaging confirmed the absence of detectable metastatic progression prior to primary tumor resection and absence of residual primary tumor after mastectomy. Mice meeting both criteria were randomized into treatment groups (B) Representative low magnification images of HE stained lung sections from IgG and anti-Ang2 antibody treated mice bearing lung metastases originating from orthotopic 4T1 breast cancer. Black arrows mark macro-metastasis and arrowheads mark micro-metastatic lesions (magnification shown in the insets). (C) Quantitation of frequency of micro-metastatic lesions in lungs (n=5; values are mean±SD; ***p≤0.001; the experiment was reproduced three times with similar results. The figure shows representative images from one of the experiment. (E) Representative Western blot analysis of ICAM-1 upon stimulation of HUVEC with rhAng2 and/or low concentration of rhTNF α compared to high rhTNFα (classical inducer of NF-kB signaling). (F) Quantification of ICAM1 protein expression after stimulation of HUVEC with rhAng2 and/or low concentrations of rhTNFα compared to high rhTNFα (n=3 replicates). (G) Cell lysates obtained from stimulated HUVEC were blotted to detect phospho-IkBα and total IkB-α. Prestarved HUVEC were stimulated by PBS (Ctrl), Ang2 (400ng/ml), low TNFα (1ng/ml) , high TNFα (10ng/ml) or a combination of Ang2 (400ng/ml) and low TNFα (1ng/ml) for 15 min prior to preparation of cell lysates. The experiment was reproduced three times with similar results. Data from one representative experiment are shown in the figure. (H) Representative images of prestarved HUVEC after stimulation with PBS (Ctrl), Ang2 (400ng/ml), low TNFα (1ng/ml) , high TNFα (10ng/ml) or a combination of Ang2 (400ng/ml) and low TNFα (1ng/ml) for 15 min to visualize nuclear translocation of p65 subunit (red). Phalloidin (green) was stained to visualize the cytoskeleton, whereas nuclei (blue) were stained with DAPI. The experiment was reproduce three times with similar results. Data from one representative experiment are shown in the figure. Values are mean±SD, *p≤0.05, **p≤0.01, ***p≤0.001, ns=non-significant. 
Supplemental Experimental Procedures
Antibody reagents: The murine-chimeric antibody anti-Ang2 was generated as a derivate of previously described human anti-Ang2 LC06 antibody (anti-murine/human Ang-2) (Thomas et al., 2013) . Murine-chimeric anti-VEGF antibody was generated based on the human anti-VEGF B20-4.1 (anti-murine/human VEGF-A) (Liang et al., 2006) . Both murinechimeric antibodies were generated by molecular fusion of human variable domains to constant antibody domains of murine IgG2a.
Antibody genes were ordered as gene syntheses and cloned via unique restriction sites harvested by centrifugation and sterile filtrated. Proteins were purified from supernatants referring to standard protocols -Protein A, ion exchange and size exclusion chromatography were applied. Purified antibodies were concentrated and diafiltrated by membrane-based tangential flow filtration. The protein concentration was determined by measuring the OD at 280 nm, using a molar extinction coefficient calculated according to Pace et al (1995) . Each antibody was analytically characterized by SDS-PAGE, size-exclusion chromatography and mass spectrometry. In addition, Surface Plasmon Resonance analysis was used to demonstrate that target specificity and high affinity of anti-Ang2 and anti-VEGF parent antibodies (Thomas et al., 2013; Liang et al., 2006) was maintained in the murine-chimeric antibodies. Antibodies were stored in 20 mM histidine, 140 mM NaCl (pH 6.0) at −80 °C at a concentration of 3 mg/ml. Endotoxin levels of both stock solutions was below 0.2 EU/ml.
Treatment regimens: Mice were treated intraperitoneally (i.p.) with the Ang2 Ab or control IgG or VEGF Ab (10mg/kg) twice a week. For combination therapy, toxicity evaluation and survival studies in 4T1 orthotopic breast cancer model, animals received Abraxane™ (Paclitaxel) for low-dose metronomic chemotherapy (6mg/kg, i.p, qd) or for maximum tolerable dose (MTD) (30mg/kg, i.p., qdx5, 1 cycle) as previously described (Ng et al., 2006) . Mice within Lewis lung carcinoma model received either Abraxane™ at low-dose metronomic chemotherapy (6mg/kg, i.p, qd) (Ng et al, 2006) or Gemcitabine (Sigma) at metronomic dosing (1mg/kg, i.p. qd) or at MTD (150mg/kg, i.p, twice a week) (Tran Cao et al., 2010) . CCL2 neutralizing antibodies (R&D) or control IgG were administered at dosage of 2mg/kg twice a week for accessing the role of CCL2 in adjuvant settings as described before (Zhu et al., 2011) . All treatments were initiated after primary tumor resection and randomization into treatment groups. CCR2 flox/flox::Mx1 Cre positive or negative mice (Willenborg et al., 2012) were treated with three injections of Poly IC (Invivogen, 250µg, i.p.) for Cre induction after primary tumor resection at day 0, 2 and 4 as previously described (Pajerowski et al., 2010) . 
Additional animal experiments

Image analysis
Vasculature analyses in metastases: Images of stained samples against CD31, SMA and DAPI were acquired with the Zeiss Cell Observer. Analysis of CD31-positive areas within each DAPI-enriched region of interest was performed using the Fiji image processing software package. Vessel size distribution was determined by filtering identified CD31+ vessels according to area in 4 categories (I: 0-100 µm2; II: 100-400 µm2; III: 400-1600 µm2;
IV: >1600 µm2). The resulting number was set to proportion to the total vessel number. Tube formation assay: Single cell suspension containing 25,000 HCMEC was added to each well of collagen matrix coated 96 well plates. The seeded cells were stimulated with either VEGF+bFGF (R&D) (positive control), recombinant Bv8 (500ng/ml) or PBS (negative control). The Bv8 treated cells were also treated with either IgG or Ang2 Ab (5,10,20ug/ml).
Images were takes using Zeiss Cell observer microscope and number of branches were analyzed using Fiji. 10 wells were analyzed per condition.
Western blot of murine tissue: For Western immunoblotting, lung metastases were dissected, chopped and homogenized in RIPA buffer using a manual tissue homogenizer.
Protein concentrations were determined and protein lysates were separated by SDS-PAGE followed by Western Blotting. Mouse ICAM-1 was detected using goat anti-mouse ICAM-1 (AF796, R&D) and actin was used as loading control. Blots were quantified using Fiji software and signals were normalized to respective loading controls.
qRT-PCR: Total RNA from lung or HUVEC lysates was extracted using the RNeasy mini kit (Qiagen) and subjected to a reverse transcriptase reaction using QuantiTect Rev.
Transcription Kit (Qiagen). cDNA was used in three replicates for qRT-PCR using predesigned TaqMan gene expression assay primers (Applied Biosystems) (mouse ICAM1:
Mm00516023_m1; mouse VCAM1: Mm01320970_m1; mouse ß-actin: Mm00607939_S1; human CCL2: Hs00234140_m1; human ß2M: Hs00984230_m1). Expression data were acquired and analyzed using an Applied Biosystems StepOne Plus Real time PCR system.
ELISA & cytokine array:
Circulating levels of serum mCCL2, mGCSF and mVEGF or CCL2
and Bv8 in protein lysates from metastatic lesions were measured using commercial ELISA kits (mCCL2,mVEGF and mGCSF from R&D and Bv8 from Cusabio®) as described by the manufacturer.
Mouse cytokine array was purchased from R&D and level of cytokines was assessed as per directions of the manufacturer. Briefly, the array membranes were blocked with blocking buffer at room temperature for 1 h, and media and the detection antibody cocktail were added and incubated at 4 °C overnight. After washing thrice with 2 ml of wash buffer at room temperature, streptavidin-HRP was added to each membrane and incubated at room temperature for 30 min. After washing, the cytokines were detected by a chemiluminescence reaction. Spots were quantified by using FIJI® after background subtraction. Normalized data were analyzed for treatment specific differences as processed and results per set were used to determine the mean differences in cytokine abundance and significance was tested using Students t-test.
